Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Immune Response after Vaccination with Recombinant Hepatitis Surface Antigen in Maintenance Hemodialysis Patients and Healthy Controls

      a , a , b , a

      Nephron

      S. Karger AG

      Hemodialysis, Immune response, rDNA-HbsAg, HBV vaccination

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We evaluated anti-HBs titers 2 months after vaccination with recombinant hepatitis surface antigen (rDNA-HBsAg) in 43 maintenance hemodialysis patients (MHP). Of these, 34 had not undergone hepatitis B virus vaccination previously (NV-MHP) and 9 had shown negative response to vaccination with plasma-derived HBsAg (HEVAC Pasteur; V-MHP). 120 healthy workers from the same hospital undergoing rDNA-HBsAg immunization were used as controls. All low responders (LR) (anti-HBs < 100 mlU/ml) and nonresponders (NR; anti-HBs < 10 mlU/ml) were given a booster dose 3 months after the last dose of vaccine. Seroconversion rates were lower in NV-MHP (52.9%) than in controls (98.4%). V-MHP showed higher seroconversion rates (88.9%) than NV-MHP. In each group, the number of responders (R; anti-HBs ≥ 100 mlU/ml), LRand NR was as follows: controls 101,17,2; NV-MHP 6,12,16; V-MHP 8,0,1. After booster dose, 17/17 controls LR and no NV-MHP LR showed a rise in anti-HBs titers over 100 mlU/ml. Six months after the last dose of vaccine or the booster dose, anti-HBs titer fell under 10 mlU/ml in 4/12 MHP LR and under 100 mlU/ml in 6/14 MHP R. To achieve high seroconversion rates and to avoid the decline of anti-HBs to nonprotective titers in MHP, a booster injection should be made at different dates after the first vaccination.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          978-3-8055-5621-7
          978-3-318-01691-8
          1660-8151
          2235-3186
          1992
          1992
          11 December 2008
          : 61
          : 3
          : 339-340
          Affiliations
          aServizio Emodialisi, bDivisione di Medicina Generale, Ospedale di Palmanova, USL no. 8 ‘Bassa Friulana’, Regione Friuli-Venezia Giulia, Palmanova, Italy
          Article
          186932 Nephron 1992;61:339–340
          10.1159/000186932
          1386908
          © 1992 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 2
          Categories
          A Special Issue on Virus Hepatitis and the Kidney

          Cardiovascular Medicine, Nephrology

          HBV vaccination, rDNA-HbsAg, Immune response, Hemodialysis

          Comments

          Comment on this article

          Similar content 71

          Cited by 5